Cutaneous Squamous Cell Carcinoma: Immune Dysfunction, Risk Stratification, and the Healthcare Team Approach- an Animated Whiteboard View
Todd E. Schlesinger, MD, FAAD
Director, Dermatology and Laser Center of Charleston, Clinical Research Center of the Carolinas
Clinical Instructor, University at Buffalo Department of Dermatology
Affiliate Assistant Professor, Medical University of South Carolina Department of Family Medicine
Clinical Preceptor, Medical University of South Carolina College of Health Professions
This online activity is focused on the management of patients with advanced or metastatic cutaneous squamous cell carcinoma.
This activity is designed to meet the educational needs of surgical dermatologists, dermatologists, and other healthcare practitioners who care for patients with advanced or metastatic cutaneous squamous cell carcinoma.
Upon the completion of this program, attendees should be able to:
- Describe the immune dysfunction present in the hyper-mutated environment of metastatic cutaneous squamous cell carcinoma
- Review the high risk factors for recurrence/metastasis in the patient with localized cutaneous squamous cell carcinoma
- Discuss the immunotherapy clinical trial data in the treatment of advanced or metastatic cutaneous squamous cell carcinoma
- Describe the multidisciplinary team communication and collaboration required to optimize the monitoring and management of the patient with localized disease at risk for recurrence
Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. This CME activity was planned and produced in accordance with the ACCME Essentials.
CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSING CREDIT INFORMATION
Purpose: This program would be beneficial for nurses involved in the care of patients with advanced or metastatic cutaneous squamous cell carcinoma. Credits: 1.0 ANCC Contact Hour(s).
CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 1.0 contact hour(s) of continuing nursing education of RNs and APNs.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF CONFLICTS OF INTEREST
Todd E. Schlesinger, MD, FAAD, has received grants/research funding from AbbVie, Aclaris, Amgen, Astellas Pharma US, Inc., Akros, Allergan, Bayer, Biofrontera, Boehringer-Ingelheim, Bristol-Meyers Squibb, Celgene, Centocur Ortho Biotech, Inc., Coherus Biosciences, Corrona, Dermira, Dermavant, Galderma (Nestle), Genentench, Inc., Janssen Pharmaceuticals, Inc., Kinex, Kiniksa, Leo, Lilly, Merz, Novartis, Pfizer, Regeneron Pharmaceuticals, Inc., Sebacia, Sienna Biopharmaceuticals, Sisaf, and Valeant Pharmaceuticals North America, LLC. Dr. Schlesinger has consulted for AbbVie Inc., (honoraria), Aclaris (honoraria), Allergan (honoraria), Bristol-Meyers Squibb (honoraria), Galderma (honoraria), Innocutis (salary), Lilly (fees), Merz (honoraria), Novartis (honoraria), Ortho Dermatologics, Pharmatecture, Prolacta Bioscience, Regeneron Pharmaceuticals, Inc. (fees), Sun Pharma, and Unilever (honoraria). Dr. Schlesinger has served on the speakers’ bureau for Aclaris, Almirall, Bayer (honoraria), Dermira (honoraria), Ilumya, LIBTAYO, ODOMZO, Regeneron Pharmaceuticals, Inc. (honoraria), Rhofade, Sanofi Genzyme, Suneva (honoraria), and Sun Pharma (honoraria). He is on the Advisory Board for Almirall (honoraria), Bioderma (honoraria), Biofrontera AG (honoraria) Greenway Therapeutix (no compensation), Remedly, Inc. (stock options), and Suneva Medical, Inc. (honoraria).
CME Content Review
The content of this activity was independently peer reviewed.
The reviewer of this activity has nothing to disclose.
CNE Content Review
The content of this activity was peer reviewed by a nurse reviewer.
The reviewer of this activity has nothing to disclose.
The staff, planners, and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:
Felecia Beachum, Program Manager for Med Learning Group has nothing to disclose.
Matthew Frese, MBA, General Manager of Med Learning Group, has nothing to disclose.
Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
Ashley Whitehurst, Program Manager of Med Learning Group, has nothing to disclose.
Lauren Welch, MA, VP, Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
Diana Tommasi, PharmD, Medical Director of Med Learning Group, has nothing to disclose.
Brianna Hanson, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CME credit for this enduring activity. To receive CME/CNE credit participants must:
1. Read the CME/CNE information and faculty disclosures.
2. Participate in the enduring activity; and
3. Complete pre-and-post surveys and evaluation.
You will receive your certificate upon completion of your evaluation form as a downloadable file.
Med Learning Group makes every effort to develop CME activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making ability before applying any information, whether provided here or by others, for any professional use.
For CME questions, please contact Med Learning Group at; firstname.lastname@example.org
Contact this CME provider at Med Learning Group for privacy and confidentiality policy statement information at: http://medlearninggroup.com/privacy‐policy/
RELEASE DATE: October 11, 2019
EXPIRATION DATE: October 11, 2020
Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.